Pleuroparenchymal fibroelastosis as a complication of chemotherapy: A case report

Data de publicação:

Autores da FMUP

  • Hélder Novais E Bastos

    Autor

  • Antonio Manuel Martins De Morais

    Autor

Participantes de fora da FMUP

  • Vieira, ACR
  • Ferra, JRM
  • De Carvalho, JSV
  • Melo, N
  • Mota, PC
  • Pereira, JM
  • Moura, CS

Unidades de investigação

Abstract

Pleuroparenchymal fibroelastosis (PPFE) is a rare and recently described distinct pattern of lung apical fibrosis involving the upper lobe parenchyma and pleural dome. PPFE has definable and reproducible clinical, radiological and histopathological criteria, which allowed its classification as an independent interstitial lung disease. Several factors have been associated with PPFE, such as chemotherapy, especially with alkylating agents. The authors present a case of a 34-year-old female with previous history of Hodgkin lymphoma treated with first line chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine). The patient had no other known comorbidities or relevant exposure to lung irritants. A total of 2 years after completing cancer treatment, the patient developed clinical and radiological features of PPFE. Given their previous history of malignancy, a biopsy of the lesion was obtained, which confirmed the diagnosis of PPFE. The authors present this case to raise awareness of this disease and to demonstrate that PPFE can develop months to years following chemotherapy treatment. Moreover, to date, none of these chemotherapy agents have been associated with the development of PPFE.

Dados da publicação

ISSN/ISSNe:
2049-9450, 2049-9469

Molecular and Clinical Oncology  Spandidos Publications UK

Tipo:
Article
Páginas:
-
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 1

Citações Recebidas na Scopus: 2

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • pleuroparenchymal fibroelastosis; chemotherapy; doxorubicin; bleomycin; vinblastine; dacarbazine

Proyectos asociados

Fibrosing ILD Biomarkers That Rule Acceleration (FIBRALUNG) -NCT05635032

Investigador Principal: Hélder Novais e Bastos

Estudo Observacional Académico (FIBRALUNG) . FCT . 2021

Chronic Bronchopulmonary aspergillosis patients with underlying chronic obstructive pulmonary disease: providing grounds for biomarkers search through clinical phenotyping

Investigador Principal: Hélder Novais e Bastos

Estudo Clínico Académico . 2020

Impact of Chronic Obstructive Pulmonary Disease in surgical outcomes of lung cancer patients undergoing curative intent surgery

Investigador Principal: Hélder Novais e Bastos

Estudo Clínico Académico . 2021

Pulmonary Emphysema Regional Distribution and Extent from Chest Computed Tomography is Associated with Pulmonary Function Impairment in COPD Patients.

Investigador Principal: Hélder Novais e Bastos

Estudo Clínico Académico . 2021

Non-invasive assessment of Benign Tracheal Stenosis.

Investigador Principal: Hélder Novais e Bastos

Estudo Clínico Académico . 2020

Citar a publicação

Partilhar a publicação